1Levy J,Atkinson AB,Bell PM,et al.Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus;the 10-year follow-up of the Belfast Diet Study[J].Diabet Med,1998,15(4):290-296
2Sa JR,Silva RC,Nasri F,et al.Non-obese adult onset diabetes with oral hypoglycemic agent failure:islet cell auto antibodies or reversible beta cell refractoriness[J].Braz J Med Biol Res,2003,36(10):1301-1309
3Kosaka K,Kobayashi T,Nakanishi K,et al.Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet patients with clinical features of NIDDM[J].Diabetes,1996,45(5):622-626
3Weir GC,Bonner-Weir S.Five stages of evolving beta-cell dysfunction during progression to diabetes[J].Diabetes,2004,53 (Suppl 3):16 -21.
4Schulze MB,Solomon CG,Rifai N,et al.Hyperproinsulinaemia and risk of type 2 diabetes mellitus in women[J].Diabet Med,2005,22 (9):1178-1184.
5Zethelius B,Lithell H,Hales CN,et al.Insulin sensitivity,proinsulin and insulin as predictors of coronary heart disease:a population-based 10-year follow-up study in 70-year old men using the euglycaemic insulin clamp[J].Diabetologia,2005,48 (5):862-867.
3[1]Levy J,Atkinson A B,Bell P M,et al.Beta-cell deterioration deter-mines the onset and rate of progression of secondary dietary failure in type2 diabetes mellitus;the 10-year follow up of the Belfast Diet Study[J].Diabet Med,1998,15(4):290-296.
4[2]Sa J R,Silva R C,Nasri F,et al.Non-obese adult onset diabetes with oral hypoglycemic agent failure:islet cdl auto antibodies or reversible beta cell refractoriness[J].Braz J Med Biol Res,2003,36(10):1301-1309.
5[4]Van den Ben e G.Endocrine evaluation of patients with critical illness[J].Endocrinol Metab Clin North Am,2003,32(2):385-410.
6[5]Pantaleo A,Zonszein J.Using insulin as u drug rather than as a replacement hormone during acute illness:a new paradigm[J].Heart Disease,2003.5(5):323-334.
7[9]Hansen T K,Thiel S,Wouters P J,et al.Intensive insulin therapy exerts antiinflammatory efects in critically ill patients and counteracts the adverse efect of low mannose-binding lectin levels[J].J Clin Endocrinol Metab,2003,88(3):1082-1088.
8[10]Van den Berghe G,Wouters P J,Bouillon R,et al.Outcome benefit of intensive insulin therapy in the critically ill:insulin dose versus glycemic control[J].Crit Care Med,2003,31(2):359-366.
10[13]Hennige A M,Strack V,Metzinger E,et al.Effects of new insulin analogues HMR1964(insulin glulisine)and HMR1423 on insulin receptors[J].Diabetologia,2005,48:1891-1897.
